QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

KALV

QT70KalVista Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
27.00
+0.00%
OverviewShort InterestFilings
KALVQT70KalVista Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
27.00+0.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.23
Insider Own13.27%
Shs Outstand53.24M
Perf Week0.19%
Market Cap1.44BForward P/E42.19EPS next Y0.64Insider Trans0.24%Shs Float-Perf Month0.75%
Enterprise Value1.49BPEG0.47EPS next Q-0.29Inst Own-Short Float-Perf Quarter59.39%
Income-145906654.00P/S12.40EPS this Y62.50%Inst Trans-Short Ratio-Perf Half Y60.14%
Sales115.91MP/B-EPS next Y152.84%ROA-41.28%Short Interest-Perf YTD67.18%
Book/sh-0.06P/C-EPS next 5Y-ROE-1057.44%52W High27.00 0.00%Perf Year100.59%
Cash/sh5.63P/FCF-EPS past 3/5Y-ROIC-46.81%52W Low9.83 174.67%Perf 3Y-
Dividend Est.-EV/EBITDA-12.74Sales past 3/5Y-Gross Margin92.03%Volatility0.05% 0.13%Perf 5Y-
Dividend TTM-EV/Sales12.88EPS Y/Y TTM-7.05%Oper. Margin-120.80%ATR (14)0.20Perf 10Y-
Dividend Ex-Date-Quick Ratio5.52Sales Y/Y TTM-Profit Margin-119.44%RSI (14)75.89Recom2.50
Dividend Gr. 3/5Y-Current Ratio5.58EPS Q/Q-1.10%SMA200.45%Beta0.67Target Price28.67
Payout0.00%Debt/Eq-104.83Sales Q/Q-SMA5011.14%Rel Volume0.00Prev Close27.00
Employees150LT Debt/Eq-50.00EarningsDec 03SMA20058.99%Avg Volume4.01MPrice27.00
IPO DateApr 09, 2015Option/ShortYes / YesEPS/Sales Surpr.4.17% -56.25%Net Debt/EBITDA-0.47Volume0Change0.00%
Analyst Ratings
DateActionAnalystRatingTarget
May-01-26ReiteratedH.C. Wainwright$37 → $27
May-01-26DowngradeHC Wainwright & Co.Buy → Neutral
Apr-30-26DowngradeNeedhamBuy → Hold
Apr-29-26ReiteratedLeerink PartnersOutperform$20 → $27
Jan-09-26ReiteratedH.C. Wainwright$27 → $37
Jan-06-26ReiteratedNeedhamBuy$28 → $32
Nov-11-25ReiteratedJMP SecuritiesMarket Outperform$29 → $28
Nov-05-24ReiteratedNeedhamBuy$38 → $28
Sep-06-24ReiteratedH.C. Wainwright$20
Sep-06-24ReiteratedLeerink Partners$20
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
12/31/2025
FY 2025
4/30/2025
FY 2024
4/30/2024
FY 2023
4/30/2023
FY 2022
4/30/2022
FY 2021
4/30/2021
FY 2020
4/30/2020
FY 2019
4/30/2019
Total Revenue116740
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A960
Gross Profit106680
Selling, General and Administrative Excl. Other199184116
Research and Development485672
Other Operating Expense0-10
Operating Income-140-172-188
Interest Expense24196
Unusual Expense
———
Non-Operating Income (Expense)-22-20-14
Net Income Before Taxes-140-171-180
Income Taxes-3-73
Consolidated Net Income-137-164-183
Net Income From Continuing Operations-137-164-183
Net Income-137-164-183
EPS (Recurring)-3.23-3.23-3.69
EPS (Basic, Before Extraordinaries)-3.23-3.23-3.69
EPS (Diluted)-3.23-3.23-3.69
EBITDA-117-151-173
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio11.8711.13—
Gross Margin91.3891.89—
Operating Margin-120.69-232.43—
Net Margin-118.10-221.62—
Shares Outstanding515150
Market Capitalization1,377824—
Operating Lease Expense
———
Insider Trading Volume
$28.66$25.22$21.78$18.34$14.90● Close Price0.00M0.95M1.90M2.85M3.80MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Yea ChristopherCHIEF DEVELOPMENT OFFICERMay 27 '26Sale26.7833,800905,225229,918May 29 12:00 AM
Yea ChristopherCHIEF DEVELOPMENT OFFICERMay 27 '26Option Exercise7.0767,600477,932263,718May 29 12:00 AM
Sweeny NicoleChief Commercial OfficerMay 26 '26Sale26.781,48939,87259,291May 27 12:00 AM
Yea ChristopherCHIEF DEVELOPMENT OFFICERMay 26 '26Sale26.781,96652,645229,918May 27 12:00 AM
Audhya Paul K.CHIEF MEDICAL OFFICERMay 26 '26Sale26.782,23959,955150,260May 27 12:00 AM
Audhya Paul K.CHIEF MEDICAL OFFICERMay 22 '26Option Exercise0.0010,0000152,499May 27 12:00 AM
Yea ChristopherCHIEF DEVELOPMENT OFFICERMay 22 '26Option Exercise0.006,2500231,884May 27 12:00 AM
Sweeny NicoleChief Commercial OfficerMay 22 '26Option Exercise0.0010,000060,780May 27 12:00 AM
Piekos BrianChief Financial OfficerMay 22 '26Sale26.781,48939,88221,661May 26 12:00 AM
Palleiko Benjamin LCHIEF EXECUTIVE OFFICERMay 22 '26Sale26.7810,926292,646479,989May 26 12:00 AM
Sweeny NicoleChief Commercial OfficerMay 22 '26Sale26.781,86149,84655,780May 26 12:00 AM
Yea ChristopherCHIEF DEVELOPMENT OFFICERMay 22 '26Sale26.782,35863,158228,759May 26 12:00 AM
Audhya Paul K.CHIEF MEDICAL OFFICERMay 22 '26Sale26.782,68571,916147,499May 26 12:00 AM
Audhya Paul K.CHIEF MEDICAL OFFICERMay 21 '26Option Exercise0.0012,5000150,184May 26 12:00 AM
Yea ChristopherCHIEF DEVELOPMENT OFFICERMay 21 '26Option Exercise0.007,5000231,117May 26 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR